TCR2 Therapeutics Inc. (TCRR)

NASDAQ: TCRR · IEX Real-Time Price · USD
2.94
+0.05 (1.73%)
At close: Jul 5, 2022 4:00 PM
3.00
+0.06 (2.04%)
After-hours: Jul 5, 2022 6:46 PM EDT

Company Description

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer.

The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma.

It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma.

The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

TCR2 Therapeutics Inc.
TCR2 Therapeutics Logo
Country United States
Founded 2015
IPO Date Feb 14, 2019
Industry Biotechnology
Sector Health Care
Employees 145
CEO Garry Menzel

Contact Details

Address:
100 Binney St
Cambridge, Massachusetts 02142-1096
United States
Phone 617 949 5200
Website tcr2.com

Stock Details

Ticker Symbol TCRR
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency US Dollars
IPO Price $15.00
CIK Code 0001750019
CUSIP Number 87808K106
ISIN Number US87808K1060
Employer ID 47-4152751
SIC Code 2836

Key Executives

Name Position
Dr. Garry E. Menzel M.B.A., Ph.D. President, Chief Executive Officer and Director
Dr. Patrick A. Baeuerle Ph.D. Founder and Member of the Advisory Board
Peter Olagunju Chief Technical Officer
Dr. Alfonso Quintas Cardama M.D. Chief Medical Officer
Richard Roomberg Vice President of Corporate Controller
Carl Mauch Senior Director of Investor Relations and Corporate Communications
Margaret Siegel J.D. Head of Legal and Corporate Secretary
Dr. Angela Justice Ph.D. Chief People Officer
Dr. Rosemary Harrison Ph.D. Chief Business and Strategy Officer
Stephen Turkowiak M.B.A. Vice President of Finance and Treasurer

Latest SEC Filings

Date Type Title
May 12, 2022 10-Q Quarterly report [Sections 13 or 15(d)]
May 12, 2022 8-K Current report
Mar 24, 2022 EFFECT Notice of Effectiveness
Mar 22, 2022 S-8 Securities to be offered to employees in employee benefit plans
Mar 22, 2022 POS AM Post-Effective amendments for registration statement
Mar 22, 2022 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
Mar 22, 2022 POSASR Post-effective Amendment to an automatic shelf registration statement
Mar 22, 2022 8-K Current report
Mar 18, 2022 4 Statement of changes in beneficial ownership of securities
Mar 18, 2022 4 Statement of changes in beneficial ownership of securities